Achieved in Just Two Weeks After Listing

Investing in Growth Potential Through the Technology Transfer Theme

Mirae Asset Global Investments announced on March 31 that the net asset value of the 'TIGER Technology Transfer Bio Active' Exchange-Traded Fund (ETF) has surpassed 100 billion won.


According to the Korea Exchange, as of the previous day's closing price, the ETF's net asset value was recorded at 114.1 billion won. Since its listing on March 17, it has expanded to a scale of 100 billion won in just about two weeks.


Mirae Asset's 'TIGER Technology Transfer Bio Active ETF' Surpasses 100 Billion Won in Net Assets View original image

The TIGER Technology Transfer Bio Active ETF is an active ETF that primarily invests in domestic KOSDAQ-listed bio companies, focusing on the 'technology transfer (license-out)' theme, which is gaining attention amid global pharmaceutical companies' competition to secure new drug pipelines. It employs an active strategy that reflects technology transfer momentum through a biotech-centric portfolio and flexibly adjusts its holdings and allocations based on the trends of global conferences and technology transfer deals.


Recently, liquidity inflows have continued in the domestic stock market as government policies to revitalize KOSDAQ and expectations for capital inflows coincide. As interest in the KOSDAQ market grows, the pharmaceutical and bio sectors, in particular, have shown relative strength. Six out of the top ten KOSDAQ-listed companies by market capitalization are pharmaceutical or bio businesses.


Mirae Asset Global Investments explained that this trend is also linked to structural changes in the global pharmaceutical industry. Major global pharma companies are increasingly introducing external technologies in response to the expiration of blockbuster drug patents, which is structurally expanding technology transfer opportunities for domestic bio companies. In practice, both the number and size of technology transfer contracts are on the rise.



Jung Wontak, Head of Equity Investment Division 3 at Mirae Asset Global Investments, stated, "As interest in the KOSDAQ market rises and the demand for technology transfer increases due to global pharmaceutical companies’ patent expirations, investment opportunities for domestic bio companies are also growing. The TIGER Technology Transfer Bio Active ETF is a product that selectively invests in companies reflecting technology transfer capabilities and global healthcare trends, serving as an effective vehicle for investing in the KOSDAQ bio growth story."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing